Browse > Article
http://dx.doi.org/10.5483/BMBRep.2018.51.11.168

MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD  

Song, Hongming (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Li, Dengfeng (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Wu, Tianqi (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Xie, Dan (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Hua, Kaiyao (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Hu, Jiashu (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Deng, Xiaochong (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Ji, Changle (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Deng, Yijun (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Fang, Lin (Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University)
Publication Information
BMB Reports / v.51, no.11, 2018 , pp. 602-607 More about this Journal
Abstract
Aberrant expression of microRNAs (miRNAs) plays important roles in carcinogenesis and tumor progression. However, the expression and biological role of miR-301b in triple-negative breast cancer (TNBC) remains unclear. Here we aimed to evaluate the roles and mechanisms of miR-301b in TNBC cells. miR-301b expression was assessed in TNBC specimens and cell lines by quantitative Real-Time PCR (qRT-PCR). TNBC cells were transfected with miR-301b mimics, inhibitors or Cylindromatosis (CYLD) small interfering RNA (siRNA) using Lipofectamine 2000. The functional roles of miR-301b were determined by cell proliferation, colony formation, and apoptosis assays. Western blots and qRT-PCR were used to measure the expression of mRNAs and proteins in the cells. We found that miR-301b was upregulated in TNBC specimens and cell lines. Overexpression of miR-301b promoted cell proliferation in TNBC cells, while inhibited the apoptosis induced by 5-FU. CYLD was downregulated by miR-301b at both mRNA and protein levels in TNBC cells. Dual-luciferase report assay confirmed that miR-301b downregulated CYLD by direct interaction with the 3'-untranslated region(3'-UTR) of CYLD mRNA. $NF-{\kappa}B$ activation was mechanistically associated with miR-301b-mediated downregulation of CYLD. However, inhibition of miR-301b reversed all the effects of miR-301b. In conclusion, miR-301b plays an oncogenic role in TNBC possibly by downregulating CYLD and subsequently activating $NF-{\kappa}B$ p65, and this may provide a novel therapeutic approach for TNBC.
Keywords
Apoptosis; Cell proliferation; CYLD; MiR-301b; TNBC;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Dawood S (2010) Triple-negative breast cancer: epidemiology and management options. Drugs 70, 2247-2258   DOI
2 Lee A and Djamgoz MBA (2018) Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev 62, 110-122   DOI
3 Fkih M'hamed I, Privat M, Trimeche M, Penault-Llorca F, Bignon YJ and Kenani A (2017) miR-10b, miR-26a, miR-146a and miR-153 expression in triple negative vs non triple negative breast cancer: Potential biomarkers. Pathol Oncol Res 23, 815-827   DOI
4 Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34, D140-144   DOI
5 Ardekani AM and Naeini MM (2010) The role of microRNAs in human diseases. Avicenna J Med Biotechnol 2, 161-179
6 Tufekci KU, Meuwissen RL and Genc S (2014) The role of microRNAs in biological processes. Methods Mol Biol 1107, 15-31
7 Calin GA, Sevignani C, Dumitru CD et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101, 2999-3004   DOI
8 Wu D, Chen B, Cui F, He X, Wang W and Wang M (2016) Hypoxia-induced microRNA-301b regulates apoptosis by targeting Bim in lung cancer. Cell Prolif 49, 476-483   DOI
9 Funamizu N, Lacy CR, Parpart ST, Takai A, Hiyoshi Y and Yanaga K (2014) MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells. Int J Oncol 44, 725-734   DOI
10 Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18, 621-663   DOI
11 Li Q and Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2, 725-734   DOI
12 Brummelkamp TR, Nijman SM, Dirac AM and Bernards R (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424, 797-801   DOI
13 Yamaguchi N, Ito T, Azuma S et al (2009) Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 100, 1668-1674   DOI
14 Biswas DK, Shi Q, Baily S et al (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101, 10137-10142   DOI
15 Sovak MA, Bellas RE, Kim DW et al (1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100, 2952-2960   DOI
16 Zhou Y, Eppenberger-Castori S, Marx C et al (2005) Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37, 1130-1144   DOI
17 Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801-805   DOI
18 Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793-796   DOI
19 Hayashi M, Jono H, Shinriki S et al (2014) Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat 143, 447-457   DOI
20 Liu M, Sakamaki T, Casimiro MC et al (2010) The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 70, 10464-10473   DOI
21 Song HM, Song JL, Li DF, Hua KY, Zhao BK and Fang L (2015) Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway. Onco Targets Ther 8, 3565-3573
22 Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM and Gao HJ (2010) Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11, 50-54   DOI
23 Sun SC (2010) CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 17, 25-34   DOI
24 Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R and Bosserhoff AK (2007) Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28, 21-27   DOI
25 Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M and Sif S (2005) The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol 25, 7953-7965   DOI
26 Massoumi R, Kuphal S, Hellerbrand C et al (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206, 221-232   DOI